首页> 外文期刊>Acta Pharmaceutica Sinica B >Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion
【24h】

Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion

机译:聚合物组合在通过热熔挤出制备热不稳定药物的固体分散体中的用途

获取原文
           

摘要

The objective of the study was to prepare solid dispersions containing a thermally unstable drug by hot-melt extrusion (HME). Carbamazepine (CBZ) was selected as model drug and combinations of Kollidon VA64 (VA64), Soluplus (SOL) and Eudragit EPO (EPO) were utilized as carriers. Preformulation was conducted to identify the suitability of polymer combinations based on solubility parameters, differential scanning calorimetry (DSC), hot stage microscopy and thermogravimetric analysis. Physicochemical properties of solid dispersions were determined by DSC, X-ray diffraction, fourier transform infrared spectroscopy, dissolution and accelerated stability testing. The results show that drug-polymer miscibility at temperatures below the melting point (T"m) of CBZ was improved by combining EPO with VA64 or SOL. With 30% drug loading in a solid dispersion in SOL:EPO (1:1, w/w), CBZ was mainly present in an amorphous form accompanied by a small amount of a microcrystalline form. The dissolution rate of the solid dispersion was significantly increased (approximately 90% within 5min) compared to either the pure drug (approximately 85% within 60min) or the corresponding physical mixture (approximately 80% within 60min) before and after storage. The solid dispersion in SOL:EPO (1:1, w/w) was relatively stable at 40^oC/75% RH under CBZ tablet packaging conditions for at least 3 months. In conclusion, polymer combinations that improve drug-polymer miscibility at an HME processing temperature below the T"m of a drug appear to be beneficial in the preparation of solid dispersions containing thermally unstable drugs.
机译:研究的目的是通过热熔挤出(HME)制备包含热不稳定药物的固体分散体。选择卡马西平(CBZ)作为模型药物,并将Kollidon VA64(VA​​64),Soluplus(SOL)和Eudragit EPO(EPO)的组合用作载体。根据溶解度参数,差示扫描量热法(DSC),热台显微镜和热重分析,进行预配制以鉴定聚合物组合的适用性。固体分散体的理化性质通过DSC,X射线衍射,傅立叶变换红外光谱,溶解度和加速稳定性测试来确定。结果表明,通过将EPO与VA64或SOL结合使用,可改善CBZ熔点(T“ m)以下温度下的药物-聚合物混溶性。在SOL:EPO(1:1,w / w),CBZ主要以无定形形式存在,并伴有少量的微晶形式,与任一纯药物(在5min内约占85%)相比,固体分散体的溶解速率均显着提高(在5min内约90%)。储存前后约60分钟)或相应的物理混合物(约60分钟内约80%)在SOL:EPO中固体分散体(1:1,w / w)在CBZ片剂包装下在40°oC / 75%RH下相对稳定总之,在HME加工温度下低于药物T'm的条件下改善药物-聚合物混溶性的聚合物组合对于制备含有热不稳定药物的固体分散体似乎是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号